drugset
drugset / Trial / NCT03351114

Pilot Study Evaluating the Efficacy of a Topical PDE4 Inhibitor for Morphea

NCT03351114 ↗

Phase 2 Completed 8 enrolled Duke University Pfizer · collab
NaSingle-groupOpen-labelTreatment

Summary

This is a pilot study to determine the safety and clinical efficacy of crisaborole 2% ointment in the treatment of morphea.

Timeline

Start
2018-09-01
Primary completion
2020-03-10
Completion
2020-03-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Crisaborole Small molecule 2 % Topical

Indications

localized scleroderma